-
Views
-
Cite
Cite
Patrice Nordmann, Juan J. Picazo, Reinier Mutters, Volkan Korten, Alvaro Quintana, Joerg M. Laeuffer, Joyce Chen Hian Seak, Robert K. Flamm, Ian Morrissey, on behalf of the COMPACT study group, Berge Azadian, Khalid El-Bouri, Graeme Jones, Bob Masterton, Marina Morgan, Beryl Oppenheim, David Waghorn, Edmond Smyth, Marianne Abele-Horn, Enno Jacobs, Uwe Mai, Reinier Mutters, Wolfgang Pfister, Christoph Schoerner, Harald Seifert, Cécile Bebear, Edouard Bingen, Richard Bonnet, François Jehl, Pierre-Yves Levy, Patrice Nordmann, Micheline Roussel Delvallez, Olga Paniara, Joseph Papaparaskevas, Heczko Piotr, Milan Kolář, Helena Žemličková, Juraj Hanzen, Daniela Kotulová, Mario Campa, Giovanni Fadda, Giacomo Fortina, Giovanni Gesu, Esther Manso, Fulvia Milano, Giuseppe Nicoletti, Leopoldo Pucillo, Roberto Rigoli, Gianmaria Rossolini, Vittorio Sambri, Mario Sarti, Halis Akalın, Melda Sınırtaş, Murat Akova, Gülşen Hasçelik, Dilek Arman, Murat Dizbay, Bilgehan Aygen, Bülent Sümerkan, Başak Dokuzoğuz, Harika Esener, Haluk Eraksoy, Seniha Başaran, İftihar Köksal, Gülçin Bayramoğlu, Volkan Korten, Güner Söyletir, Sercan Ulusoy, Alper Tünger, Ata Nevzat Yalçın, Dilara Öğünç, Germán Bou, Emilio Bouza, Rafael Canton, Pere Coll, José Ángel García-Rodriguez, Concepción Gimeno, Miguel Gobernado, Frederic Gomez Bertomeu, José Luis Gómez-Garcés, Francesc Marco, Luis Martínez-Martínez, Alvaro Pascual, José Luis Pérez, Juan Picazo, Guillem Prats, Maria Saumoy Linares, Farid Ghaly, Melo Cristino, Jose Diogo, Helena Ramos, Arta Balode, Marika Jürna-Ellam, Roman Koslov, Comparative activity of carbapenem testing: the COMPACT study, Journal of Antimicrobial Chemotherapy, Volume 66, Issue 5, May 2011, Pages 1070–1078, https://doi.org/10.1093/jac/dkr056
Close - Share Icon Share
Abstract
Doripenem is a new carbapenem recently introduced into Europe. The COMParative Activity of Carbapenem Testing (COMPACT) study compared the susceptibility of common Gram-negative bacilli causing serious infections in hospitalized patients with doripenem, imipenem and meropenem.
Gram-negative isolates (4498 total: 2171 Pseudomonas species; 1910 Enterobacteriaceae; and 417 other Gram-negative bacilli) were collected from 80 centres in 16 countries in Europe, the Middle East and Africa during 2008–09. The MICs of doripenem, imipenem and meropenem were determined using Etest methodology and broth microdilution. Susceptibility was interpreted according to CLSI, EUCAST and FDA breakpoints.
The MIC90s of doripenem, imipenem and meropenem for all isolates were 8, ≥64 and 32 mg/L, respectively. Doripenem had the lowest MIC90 for Pseudomonas species at 16 mg/L, with imipenem and meropenem values of ≥64 mg/L. Enterobacteriaceae were highly susceptible to all three carbapenems, with MIC90s of doripenem, imipenem and meropenem of 0.06, 0.5 and 0.12 mg/L, respectively. Other Gram-negative isolates, predominantly Acinetobacter baumannii, were resistant to all three carbapenems (MIC90 ≥64 mg/L). Susceptibility to doripenem was observed in 14.9% of isolates resistant to imipenem and/or meropenem.
Doripenem showed excellent activity against Gram-negative isolates; generally it was more active than imipenem and at least as good as meropenem. Against Pseudomonas species, doripenem was more active than both imipenem and meropenem, with doripenem susceptibility observed for some imipenem- and/or meropenem-resistant isolates.
